CJC-1295 no DAC research: quick summary
CJC-1295 no DAC is the trade name applied to modified GRF (1-29), a tetrasubstituted 29-residue analogue of human growth hormone releasing hormone, supplied by Red Leaf Research Labs as a 10 mg lyophilized research material. Despite the shared name it is a different molecule from CJC-1295 with DAC. It is not an authorized medicine in Canada, is for laboratory research use only, is not for human or veterinary use, and carries no dosing or protocol information.
CJC-1295 no DAC Canada: CJC-1295 no DAC 10mg Research Product
Modified GRF (1-29), sold under the CJC-1295 no DAC label, is stocked in a 10 mg fill for qualified laboratory purchasers in Canada. Material, lot paperwork and dispatch terms follow.
People arrive here on buy CJC-1295 no DAC Canada, mod GRF 1-29 peptide Canada and modified GRF 1-29 Canada. Those queries are recorded, not endorsed. A personal-health motive belongs with a clinician.
Red Leaf Research Labs supplies this material as a research chemical. It is not offered for use in people or animals, arrives with no dosing figure, and no claim about its activity is made.
CJC-1295 no DAC 10mg Research Format and Options
| Attribute | Detail |
|---|
| Research format | One vial, 10 mg modified GRF (1-29), lyophilized |
| Physical state | Freeze-dried cake or powder, vial sealed |
| Analytical documentation | Outside laboratory report for this lot, methods stated |
| Fulfilment | Carriage within Canada, research addresses |
| Intended use | Laboratory research only; not for human or veterinary use |
The 10 mg figure describes the container, not a protocol. No advice is given on how much of it any study needs.
CJC-1295 no DAC Research Specifications
- Compound name: Modified GRF (1-29)
- Alternative name(s): CJC-1295 without DAC, mod GRF 1-29
- Research shorthand: Mod GRF 1-29
- Peptide/compound class: Synthetic GHRH analogue, 29-residue C-terminal amide
- Receptor or pathway interest: GHRH receptor (GHRHR), anterior pituitary somatotrophs
- Structural origin: Human GRF(1-29) amide with D-Ala2, Gln8, Ala15, Leu27
- CAS: 863288-34-0
- Molecular formula: C152H252N44O42
- Molecular weight: approximately 3367.9 g/mol
- Physical format: Solid, freeze-dried
- Available research quantity: 10 mg per vial
- Intended use: Laboratory research use only
- Fulfilment: Carriage within Canada only
What Is CJC-1295 no DAC?
The material sold under this name is modified GRF (1-29): the first twenty-nine residues of human growth hormone releasing hormone, ending in a C-terminal amide, and four changed positions: D-alanine at 2, glutamine replacing asparagine at 8, alanine at 15, leucine at 27. Nothing further is attached. Formula C152H252N44O42, mass about 3367.9.
The compound it is confused with is CJC-1295 with DAC, CAS 446262-90-4, C165H269N47O46, mass about 3647.2. That molecule carries a thirtieth residue, a lysine bearing a maleimidopropionyl group, which is the drug affinity complex the name refers to. Roughly 280 daltons and a reactive functional group separate the two. Sermorelin, plain GRF(1-29) amide, is a third compound.
CJC-1295 no DAC and GHRH Receptor Research
Published work on GRF(1-29) analogues concerns the growth hormone releasing hormone receptor of anterior pituitary somatotrophs, a class B G protein-coupled receptor characterised by adenylate cyclase coupling and cyclic AMP generation. The N-terminal region is described as the part required for receptor activation. The literature discusses D-alanine at position 2 in relation to dipeptidyl peptidase-4 cleavage, and the glutamine and leucine substitutions in relation to chemical liabilities at the native asparagine and methionine positions.
Those are measurements in receptor preparations, pituitary cell cultures and animal models. Receptor activity in a model does not establish that any effect occurs in a person.
Why Buy CJC-1295 no DAC 10mg in Canada from a Domestic Research Supplier?
Shipping time is the plain argument. A dry cake travels better than a solution, but a border hold is the part of a route nobody can document afterwards.
Accountability is the sharper argument here. The market attaches this trade name to two molecules, so a buyer wants a seller who can be asked in writing which is in stock.
These are commercial points. A short route raises no purity and answers nothing the report leaves open.
How This CJC-1295 no DAC Canada Page Improves on Typical Competitor Listings
Many listings reuse a template and fill in a name, which is how the naming problem spreads. This page differs in five ways.
- The copy describes the sequence, its four named substitutions and its C-terminal amide, not generic peptide language.
- The analytical basis is stated, not asserted: a report tied to the lot in stock and its methods.
- There is no statement of effect, advantage or safety anywhere in this description.
- The regulatory position is explicit: a research chemical, not an authorized medicine.
- Structural relationships are given with figures, so the DAC and no-DAC materials can be told apart by CAS and mass rather than trade name.
How to Evaluate a CJC-1295 no DAC Certificate of Analysis
This certificate does identity work before anything else. A second subtlety follows: the C-terminus is an amide, and the free acid differs by about one dalton.
- Compound identity: modified GRF (1-29), or CJC-1295 without DAC, quoted against CAS 863288-34-0.
- Lot reference: the lot code on the certificate is the code on the vial you were sent.
- Analysis date: when the sample was run, not when the document issued.
- Test methods: the chromatography described, and whether the mass instrument resolves amide from free acid.
- Measured quantity: the mass the certificate accounts for, set against the 10 mg claimed.
- Purity result: the percentage with its method and detection wavelength attached.
- Laboratory verification: which laboratory did the work, and whether it is separate from the seller.
The decisive number is mass: about 3368 here, about 3647 for the conjugate sold under the fuller name.
CJC-1295 no DAC 10mg Lyophilized Research Format
The vial holds a freeze-dried cake: frozen, then held under reduced pressure until the ice passed straight to vapour. Dryness slows backbone hydrolysis in storage.
Two of the four substitutions are themselves degradation chemistry. Glutamine replaces asparagine at 8, removing a residue the literature regards as a deamidation site, and leucine replaces methionine at 27, removing one prone to oxidation. The rest is ordinary: humidity, temperature cycling, light, freeze-thaw once dissolved. The supplier note on this item calls for advanced reconstitution technique, which means an institutionally validated procedure.
How to Buy CJC-1295 no DAC in Canada for Qualified Research
- Confirm eligibility. Verify your organization may receive research chemicals for the proposed lawful work.
- Review documentation. Read the lot report and check it names the molecule without the drug affinity complex.
- Select quantity. Count the 10 mg vials your written plan calls for.
- Check shipping route. Compare the route and transit window against your receiving hours.
- Record receipt. Log the lot code, arrival date and vial condition as unpacked.
These are purchasing and record steps. Nothing in them amounts to dosing or study-design advice.
CJC-1295 no DAC Availability in Canada: Research vs. Consumer Searches
Two audiences search this name. One is laboratory purchasing, needing a material identified by CAS and mass. The other is personal interest, from forums where these peptides are discussed in terms this listing will not use.
Neither modified GRF (1-29) nor CJC-1295 with DAC is an authorized medicine in Canada. Neither has been assessed by Health Canada for any use in a person, and neither has approved labelling or a prescribing framework. This vial is a laboratory reagent.
A personal-health interest in either molecule belongs with a licensed clinician, not with this listing.
CJC-1295 no DAC 10mg Canada Procurement Checklist
| Check | What to confirm |
|---|
| Purpose | Laboratory research in an eligible receiving organization |
| Identity | CAS 863288-34-0 on the label and repeated on the lot report |
| Distinctness | Mass about 3368, so not the 3647 conjugate and not sermorelin |
| Quantity | Number of 10 mg vials fixed by the written plan |
| Documentation | Lot report naming the separation and the mass method |
| Verification | Whether an outside laboratory confirms the identity call |
| Handling | A validated reconstitution procedure agreed before opening |
Explore CJC-1295 no DAC Research Information
Background reading: research peptide terminology, peptide half-life, and what third-party testing tells a purchaser.
CJC-1295 no DAC research FAQ
Does Red Leaf Research Labs provide dosing information?
No. No dosing, reconstitution volume, concentration, route or protocol is provided for this or any product.
Is CJC-1295 no DAC the same molecule as CJC-1295 with DAC?
No. This is modified GRF (1-29), CAS 863288-34-0, C152H252N44O42. The DAC material is CAS 446262-90-4, C165H269N47O46.
Why do two different compounds share the name CJC-1295?
The trade name belonged to the DAC conjugate and was then applied to the underlying 29-residue sequence with “no DAC” appended. The usage is entrenched and inaccurate.
How does modified GRF (1-29) differ from sermorelin?
Sermorelin is GRF(1-29) amide with no substitutions. This material carries four: D-Ala2, Gln8, Ala15, Leu27.
What documentation comes with the 10mg vial?
An outside laboratory report covers the lot held, keyed to its number and naming each technique used.
Research use only. CJC-1295 no DAC (modified GRF 1-29) 10 mg is supplied strictly for laboratory research. It is not an authorized medicine in Canada, is not for human or veterinary use, and carries no dosing or protocol information. Anyone with a personal-health question should consult a licensed clinician.
Independent third-party testing
Janoshik Lab Reports
Review available analytical reports associated with this product.
ANALYTICAL
REPORT
Independent analysis
CJC-1295 no DAC (mod GRF 1-29)
- Purity
- 99.754%
- Tested quantity
- 9.78 mg
- Report date
- March 25, 2026
- Task ID
- #123260
A certificate describes the submitted sample shown in that report. It does not establish clinical safety, efficacy, or suitability for human or veterinary use.
Owned and operated by a cf veteran 
